Nahui Samanta Najera-Segura

Ms. Nahui Samanta Najera-Segura

Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSERGIO ARAEL MENDOZA CALDERON
SERGIO ARAEL MENDOZA CALDERON
HCHolanda Cruz-Luis
Holanda Cruz-Luis
Laura Pérez-Campos MayoralLaura Pérez-Campos Mayoral
Laura Pérez-Campos Mayoral
IMItzel Patricia Vásquez Martínez
Itzel Patricia Vásquez Martínez
Eduardo Perez-CamposEduardo Perez-Campos
Eduardo Perez-Campos
Hector Alejandro Cabrera-FuentesHector Alejandro Cabrera-Fuentes
Hector Alejandro Cabrera-Fuentes
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily driven by chronic inflammation from viral hepatitis, metabolic dysfunction, alcohol-induced liver disease, and cirrhosis. Conventional therapies often fail in advanced stages, highlighting the need for mechanism-based, precision-guided interventions. Plant-derived secondary metabolites represent a promising class of bioactive compounds with structural diversity, multitarget activity, anti-inflammatory effects, and favorable toxicity profiles. This review follows a semi-systematic narrative that synthesizes preclinical and experimental evidence on the anti-inflammatory and anticancer properties of key phytochemicals, including epigallocatechin-3-gallate, galangin, resveratrol, quercetin, curcumin, berberine, genistein, and thymoquinone. These compounds consistently modulate critical inflammation-driven signaling pathways, PI3K/AKT/mTOR, NF-κB, JAK/STAT, Wnt/β-catenin, and MAPK, resulting in apoptosis induction, cell cycle arrest, inhibition of angiogenesis, and reduced invasion and metastasis in multiple HCC models. Despite strong preclinical evidence, clinical translation remains limited by variable bioavailability, incomplete safety data, and insufficient human studies. A staged development strategy is recommended: standardized formulations, Good Laboratory Practice-compliant pharmacokinetic/toxicology studies, validation in patient-derived models, and early-phase, biomarker-guided clinical trials with combination therapy arms. Addressing regulatory, manufacturing, and quality control considerations will be essential for advancing these compounds as adjuvant or complementary agents in precision HCC therapy.

17 July 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
Nahui Samanta Najera-SeguraNahui Samanta Najera-Segura
Nahui Samanta Najera-Segura
Hector Alejandro Cabrera-FuentesHector Alejandro Cabrera-Fuentes
Hector Alejandro Cabrera-Fuentes
In this commentary, we analyze the findings of Cao et al. (2025) (1) and their implications for redefining metabolic risk assessment in non-obese adults. We focus on the Atherogenic Index of Plasma (AIP) as a valuable predictive tool for metabolic risk, its clinical applicability, and the critical need for further research to address current gaps in knowledge. The study highlights a crucial aspect of metabolic health—the risk of type 2 diabetes mellitus (T2DM) in individuals who, despite not meeting the BMI criteria for obesity, may still present with elevated metabolic risk factors.Expanding the Role of AIP in People Without ObesityBody Mass Index (BMI) is commonly used to evaluate metabolic risk, but it is clear that BMI alone does not capture the full picture. Many individuals classified as underweight or normal weight still develop metabolic disorders, suggesting the need for additional markers. Although the present commentary focuses on non-obese individuals, it is essential to acknowledge that AIP has also demonstrated strong associations with metabolic dysfunction in overweight and obese populations. Li et al. (2024), in a cohort of over 40,000 Chinese adults with elevated BMI, reported a J-shaped relationship between AIP and type 2 diabetes, with inflammatory mediators such as neutrophils and monocytes partially explaining the observed risk gradient (2). Complementarily, Karimpour Reyhan et al. (2024) identified AIP as the most accurate lipid index for detecting overweight and obesity in patients with T2DM, outperforming conventional lipid ratios with an AUC of 0.770 (3). These findings underscore the broader applicability of AIP as a biomarker of cardiometabolic risk, irrespective of adiposity status. Large-scale studies have further demonstrated that AIP is a strong predictor of metabolic risk even in non-obese individuals. Huang et al. (2024) analyzed data from over 85,000 normoglycemic adults with BMI <25 kg/m² and found a significant non-linear association between the TG/HDL-C ratio—a surrogate for AIP—and incident diabetes, with an inflection point at 1.36 (4). Similarly, Wu et al. (2022) reported a robust association between AIP and prediabetes in non-obese individuals with normal LDL-C levels, identifying a clinically relevant threshold at 1.617 (5). These findings support broader evidence indicating a non-linear relationship between AIP and diabetes risk, suggesting that even in the absence of obesity, elevated AIP levels may strongly predict increased predisposition to developing T2DM(1). However, the exact physiological mechanisms underlying this association remain to be fully elucidated. Given that AIP primarily reflects the triglyceride-to-HDL-C ratio, it is likely that chronic dyslipidemia, low-grade inflammation, and insulin resistance contribute to the observed link with diabetes (6, 7). Further exploration of these pathways is necessary to determine whether AIP is simply a surrogate marker or an independent metabolic risk factor. A recent cohort study further supports this association, demonstrating that higher AIP levels predict long-term diabetes risk even among individuals with normal fasting plasma glucose(8). The new consensus published by The Lancet Diabetes & Endocrinology (2025) advocates for a shift away from BMI-centric definitions of obesity, emphasizing metabolic dysfunction as a key diagnostic criterion (9). Despite this growing consensus, there remains significant debate on the best markers to replace BMI in clinical practice. Some researchers argue that waist-to-hip ratio, visceral fat quantification, and insulin resistance indices may offer more robust predictive value than AIP alone (10, 11). Comparative studies between these markers and AIP would be valuable to determine the optimal screening approach.Clinical Implications and Integration into PracticeCao et al. (2025) (1) identified a non-linear association between AIP and diabetes risk, with a threshold at AIP = -0.268. Individuals with AIP values above this point had a significantly higher risk of developing diabetes (HR 1.763, 95% CI: 1.210-2.568, p = 0.003) (1). This suggests the potential value of incorporating AIP into standard blood test panels and combining it with established tools such as the Framingham Risk Score. A summary comparison of AIP and traditional lipid markers is presented in Table 1.Compared to traditional lipid markers like LDL-C, HDL-C, and triglycerides, AIP integrates the ratio between triglycerides and HDL-C, potentially offering more nuanced insight into lipid-driven metabolic risk (12). Although its predictive potential is promising, several limitations must be addressed before clinical adoption. One key concern is the lack of standardization in AIP cut-off values across different populations (13). Given that lipid profiles vary by ethnicity, dietary habits, and genetic background, a one-size-fits-all approach may not be appropriate (14, 15). Furthermore, the stability of AIP over time has not been well characterized—fluctuations in triglyceride and HDL-C levels due to acute illness, dietary changes, or medication use could impact AIP’s reliability. AIP has also been linked to insulin resistance and beta-cell dysfunction, two key mechanisms in T2DM development (12, 16). This supports the notion that AIP is more than just a lipid ratio; it may reflect deeper metabolic disturbances related to lipid metabolism and inflammation. However, its added predictive value over existing risk models such as HOMA-IR (17) or the triglyceride-glucose index (18) remains unclear. Large-scale comparative studies are needed to determine whether AIP offers a distinct advantage or simply mirrors existing markers. Current evidence suggests that AIP is directly associated with prediabetes development, although the relationship appears to be non-linear. Zheng et al. (2023) found that AIP values ≤ 0.03 were significantly associated with...

26 March 2026 in BMJ Global Health
Verified
Journal Article
Open access
Hector Alejandro Cabrera-FuentesHector Alejandro Cabrera-Fuentes
Hector Alejandro Cabrera-Fuentes
MHMaría Teresa Hernández Huerta
María Teresa Hernández Huerta
FGFrancisco Gutiérrez-Delgado
Francisco Gutiérrez-Delgado
VLVictor Hugo López López
Victor Hugo López López
JEJesus Elizarrarás-Rivas
Jesus Elizarrarás-Rivas
GAGuillermo Aquino-Jarquin
Guillermo Aquino-Jarquin
Preventable mortality remains a critical public health challenge in Mexico, with 819 672 deaths recorded in 2024. Of these, 37.21% in the general population were attributed to ischaemic heart disease (IHD) and diabetes mellitus. We analyse Instituto Nacional de Estadística y Geografía mortality data to assess disparities in cardiovascular mortality across age groups, sex and geographical regions, and to identify key gaps in Mexico’s preventive care strategies. Age-standardised mortality rates (ASMRs) reveal persistently elevated cardiovascular mortality in northern states, including Chihuahua, Coahuila, Durango and Nuevo León, and in southeastern states, including Veracruz, Tabasco, Campeche and Yucatán. The burden is highly concentrated among older adults and geographically clustered in specific high-risk regions. These patterns reflect structural gaps in prevention, early detection and access to adequate care rather than unavoidable demographic change. Obesity, diabetes and hypertension form a pathophysiological triad that synergistically exacerbates cardiovascular disease through shared mechanisms and comorbidities. Despite substantial global declines in IHD mortality over the past two decades, Mexico continues to experience elevated and regionally extreme cardiovascular mortality, highlighting a failure to translate established global evidence into national practice. Drawing on evidence-based interventions implemented in comparable health systems, we propose seven scalable strategies: (1) expanding access to health services in underserved regions, (2) integrating preventive health programmes within primary care, (3) developing structured physical activity initiatives, (4) establishing a geriatric care framework, (5) promoting community-based nutrition and wellness programmes, (6) advancing gender-sensitive cardiovascular prevention across adulthood and ageing and (7) implementing school-based health education programmes. These interventions could substantially reduce cardiovascular mortality, lower healthcare costs and improve long-term population health outcomes in Mexico.

18 April 2019 in Latin american journal of clinical sciences and medical technology
Verified
Journal Article
Open access
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
Eduardo Perez-CamposEduardo Perez-Campos
Eduardo Perez-Campos
María Teresa Hernández-HuertaMaría Teresa Hernández-Huerta
María Teresa Hernández-Huerta
Laura Pérez-Campos MayoralLaura Pérez-Campos Mayoral
Laura Pérez-Campos Mayoral
SMSonia Moreno-Cabral
Sonia Moreno-Cabral
Efrén Emmanuel Jarquín-GonzálezEfrén Emmanuel Jarquín-González
Efrén Emmanuel Jarquín-González
Recent genomic research from the Mexican Biobank (MXB) highlights the importance of large - scale population datasets for understanding genetic variation in Mexican and Hispanic populations. In parallel, the oriGen Project has emerged as another large - scale initiative to generate genomic data from Mexican adults, establishing one of the country’s largest genomic biobanks. Although both initiatives share the goal of expanding population genomics resources, they differ substantially in their institutional structures, governance frameworks, and data access models. While MXB operates within a public institutional framework, the oriGen Project is organized under a private governance model that includes irreversible consent provisions and international commercial sequencing partnerships. This perspective article examines the ethical, legal, and governance implications of these arrangements, particularly regarding genomic sovereignty and public interest. We argue that controlled - open access models managed by private entities, particularly when they incorporate high fees and exemption mechanisms whose eligibility, scope, approval criteria, coverage, and application are not fully public or auditable, can restrict local scientific participation and favor asymmetries in the appropriation of national genomic value.

31 December 2025 in Discoveries
Verified
Journal Article
Open access
ZRZeus Gómez Rodríguez
Zeus Gómez Rodríguez
STSaira Karina Ramírez Thome
Saira Karina Ramírez Thome
RCRisk Díaz Castillejos
Risk Díaz Castillejos
EGEunice Daysi García-Reyes
Eunice Daysi García-Reyes
AMAdrián Martínez-Vargas
Adrián Martínez-Vargas
CZCésar Zárate-Ortiz
César Zárate-Ortiz
The paradigm of dental medicine is shifting from a reactive surgical model to precision pediatric caries diagnostics, emphasizing early detection of pathogenic oral microbiota. Rapid point-of-care assays capable of identifying high-density Streptococcus mutans are critical to enable targeted intervention. This pilot study evaluated the diagnostic validity of a high- threshold monoclonal antibody-based lateral flow assay (Saliva-Check Mutans, SCM) relative to selective culture for identifying clinically meaningful S. mutans loads in children. Stimulated saliva samples were collected from 50 schoolchildren aged 9-13 years in Oaxaca, Mexico. Samples were analyzed using SCM and selective culture on Mitis Salivarius Agar (MSA), with presumptive S. mutans colonies confirmed biochemically. Selective culture identified 46% of participants as positive, whereas SCM detected 18% as positive. Relative to culture, SCM demonstrated 39.1% sensitivity (95% CI: 21.5%–60.1%), 100% specificity (95% CI: 87.5%–100%), and 100% positive predictive value (95% CI: 66.4%–100%), with no false positives observed. The results highlight the assay’s rule-in capability for high-density pathogenic loads (>10^5 CFU/mL). The diagnostic discordance reflects divergent analytical thresholds, termed the “Threshold Gap”. While SCM exhibits limited sensitivity for low-level colonization, its absolute specificity supports its use as a precision high-threshold triage tool, identifying pediatric patients with clinically significant S. mutans burdens who may benefit from intensified preventive strategies. Integration with culture or molecular approaches can enhance risk stratification and precision dentistry workflows.